134 Washington Street, Norwell MA 02061



cosmetic surgery | anti-aging center 


Viveve was NOT one of the seven companies included in the FDA vaginal rejuvenation safety statement and has NOT received a warning letter. 

The ViveveĀ® System is the only radiofrequency device on the market with cryogen cooling and preclinical studies demonstrating no injury to vaginal or surrounding tissues.

Viveve currently has regulatory approvals or clearances in over 50 countries for the treatment of vaginal laxity and/or sexual function and in Argentina, for the treatment of mild stress urinary incontinence. 

Viveve is the only company that has completed a randomized, blinded, multi-center clinical trial that has been published in 2 peer-reviewed journals reporting the safety and efficacy our CMRF device for the treatment of vaginal laxity and sexual function.